Key points from article :
Luxturna (voretigene neparvovec, for retina treatment, has been approved by NICE.
With less than 90 people eligible for treatment in England.
For those with retinal dystrophy due to inheriting faulty RPE65 gene from both parents.
Injection is made into back of the eye which delivers working copies of RPE65 gene.
Contained inside a harmless virus, enables them to penetrate the retinal cells.
Gene provides instructions to make RPE65 protein, essential for healthy vision.
Treatment is only suitable for patients who have some remaining vision.
Unknown yet how long the benefits will last, it could be several decades.
